ALK and non-small cell lung carcinoma: The purpose of this review is to provide a comprehensive overview of the main promising therapeutic targets beyond EGFR, ALK, ROS1 and BRAF and to discuss their potential implications in reshaping the current treatment algorithm for stage advanced NSCLC.